MolNFT v2 · #183951 · protein
Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 1
7K0M: “Human serine palmitoyltransferase complex SPTLC1/SPLTC2/ssSPTa/ORMDL3, class 1”. Electron microscopy at 2.9, 2 ligands (POV, PLP). MolNFT v2 #183951 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 7K0M
- Type
- protein
- Length
- 2,342 residues
- Chains
- 8
- Method
- electron microscopy
- Collection
- MolNFT v2 / PDB Bank
- Contract
- 0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
- Owner
- 0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
- Resolution
- 2.9
- Source
- Homo sapiens
- UniProt
- O15269, O15270, Q969W0, Q8N138
- Ligands
- POV, PLP
Structure
electron microscopy · resolution 2.9 · 4 distinct chains.
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, E | — | protein | 464 | — | O15269 |
| B, F | — | protein | 492 | — | O15270 |
| C, G | — | protein | 62 | — | Q969W0 |
| D, H | — | protein | 153 | — | Q8N138 |
Ligands and binding sites
- POV · (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate · ligand · 14 copies · chains B, C, D, G, H, F
- PLP · Pyridoxal-5'-phosphate · ligand · 2 copies · chains A, B, E, F
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Compared structures
- 7K0M · Human serine palmitoyltransferase complex SPTLC1/SPLTC2/SSSPTA/ORMDL3, class 1 · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt O15269
- Every structure of UniProt O15270
- Every structure of UniProt Q969W0
- Every structure of UniProt Q8N138
- Elsewhere: RCSB PDB 7K0M · PDBe 7K0M · UniProt O15269 · UniProt O15270 · UniProt Q969W0 · UniProt Q8N138
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.